Physician profile
Derek Peter Vanveen
NPI 1518177708
$3,832.19
in general payments reported to CMS, 2019-2025
25 companies · $688 in 2025
The $688 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $202 · 2021: $270 · 2022: $521 · 2023: $941 · 2024: $794 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286 · Entertainment: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,285.76 |
| Entertainment | $137.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $497.34 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $445.39 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $352.78 | 2022-2024 | |
| Coopervision INC. | $279.10 | 2020-2024 | Myday Contact Lens |
| Sight Sciences, INC. | $256.01 | 2020-2025 | Tearcare System |
| Oyster Point Pharma, INC. | $251.29 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $245.06 | 2024-2025 | Oxervate |
| Optos, INC. | $234.08 | 2022-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Mallinckrodt Hospital Products INC. | $121.87 | 2023 | Acthar |
| Bausch & Lomb Americas INC. | $120.00 | 2023 | Miebo |
| Horizon Therapeutics Plc | $120.00 | 2023 | Tepezza |
| Amgen INC. | $118.52 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $111.79 | 2025 | Xdemvy |
| Allergan, INC. | $106.48 | 2020-2022 | |
| Lkc Technologies, INC. | $102.74 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $97.51 | 2020-2025 | |
| Integra Lifesciences Corporation | $85.32 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $77.44 | 2021 | |
| Notal Vision, INC. | $49.96 | 2025 | Foresee Home |
| Astellas Pharma US INC | $46.23 | 2024 | Izervay |
| Kala Pharmaceuticals, INC. | $34.93 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $22.94 | 2024 | |
| Abbvie INC. | $21.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.93 | 2022 | |
| Shire North American Group INC | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Vanveen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.